三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图20、塔拉妥单抗的抗肿瘤机制
图20、塔拉妥单抗的抗肿瘤机制
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:543KB
图片尺寸:1205*747
同报告图片
/
4
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
PHxiZWdpbl9vZl9ib3h8Pnwg6I2v54mpICAgICAgICAgfCDpnbbngrkgICAgICAgICAgIHwg5YWs5Y+4ICAgICAgICAgICAgIHwg6YCC5bqU55eHICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5Lit5Zu95pyA6auY6Zi25q61IHwg5Lit5Zu95pyA6auY6Zi25q615byA5aeL5pe26Ze0IHwg576O5Zu95pyA6auY6Zi25q61ICAgfCDnvo7lm73mnIDpq5jpmLbmrrXlvIDlp4vml7bpl7QgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgcmlsdmVnb3N0b21pZyB8IFRJR0lUO1BEIC0gMSAgICB8IOmYv+aWr+WIqeW6tyAgICAgICAgIHwg6IOG6YGT55mMO+mdnuWwj+e7huiDnuiCuueZjDvog4PnmYwgO+iCnee7huiDnueZjDvlrZDlrqvlhoXohpznmYznrYkgfCDihaLmnJ/kuLTluoogICAgICB8IDIwMjMgLSAxMCAtIDMxICAgICAgIHwg4oWi5pyf5Li05bqKICAgICAgICB8IDIwMjMgLSAxMCAtIDMxICAgICAgIHwKfCBaRzAwNSAgICAgICAgfCBUSUdJVDtQRCAtIDEgICAgfCDms73nkp/liLboja8gICAgICAgICB8IOiCnee7huiDnueZjDvog4bpgZPnmYw75a6r6aKI55mMO+elnue7j+WGheWIhuazjOiCv+eYpOetiSAgICAgICB8IOKFoeacn+S4tOW6iiAgICAgIHwgMjAyNCAtIDA4IC0gMTYgICAgICAgfCDkuLTluorliY0gICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgfAp8IElCSTMyMSAgICAgICB8IFRJR0lUO1BEIC0gMSAgICB8IOS/oei+vueUn+eJqTvnpLzmnaUgICAgfCDnmYznl4c75a6e5L2T55ikICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOKFoOacn+S4tOW6iiAgICAgIHwgMjAyMSAtIDA1IC0gMjUgICAgICAgfCDkuLTluorliY0gICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgfAp8IEJDMDA4IC0gMUEgICB8IFRJR0lUO1BEIC0gMSAgICB8IOatpemVv+WItuiNryAgICAgICAgIHwg5a6e5L2T55ikO+mrmOe6p+WIq+iDtui0qOeYpDvpnZ7lsI/nu4bog57ogrrnmYw76aOf566h6bOe54q257uG6IOe55mM562JIHwg4oWg5pyf5Li05bqKICAgICAgfCAyMDIzIC0gMDIgLSAwMiAgICAgICB8IOS4tOW6iuWJjSAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICB8CnwgSExYMzAxICAgICAgIHwgUEQgLSBMMTtUSUdJVCAgIHwg5aSN5a6P5rGJ6ZyWICAgICAgICAgfCDlpLTpoojpg6jps57nirbnu4bog57nmYw76Z2e5bCP57uG6IOe6IK655mMO+Wwv+i3r+S4iuearueZjCA76IOD55mMIOetiSB8IOKFoC/ihaHmnJ/kuLTluoogICAgfCAyMDIyIC0gMDUgLSAyNSAgICAgICB8IOS4tOW6iuWJjSAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICB8CnwgUE0xMDIyICAgICAgIHwgUEQgLSBMMTtUSUdJVCAgIHwg5pmu57Gz5pavO0FkaW1hYiAgICB8IOeZjOeXhyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg4oWgL+KFoeacn+S4tOW6iiAgICB8IDIwMjIgLSAwNiAtIDAxICAgICAgIHwg5Li05bqK5YmNICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgIHwKfCBIQjAwMzYgICAgICAgfCBQRCAtIEwxO1RJR0lUICAgfCDljY7ljZrnlJ/niakgICAgICAgICB8IOmdnuWwj+e7huiDnuiCuueZjCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOKFoC/ihaHmnJ/kuLTluoogICAgfCAyMDIyIC0gMDYgLSAxNCAgICAgICB8IOKFoC/ihaHmnJ/kuLTluoogICAgICB8IDIwMjIgLSAwNiAtIDE0ICAgICAgIHwKfCBTSFMwMDYgICAgICAgfCBQRCAtIEwxO1RJR0lUICAgfCDlnKPlkozoja/kuJogICAgICAgICB8IOWunuS9k+eYpCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOKFoOacn+S4tOW6iiAgICAgIHwgMjAyMiAtIDA2IC0gMTUgICAgICAgfCDkuLTluorliY0gICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgfAoK5pWw5o2u5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5YW05Lia6K+B5Yi457uP5rWO5LiO6YeR6J6N56CU56m26Zmi5pW055CGPHxlbmRfb2ZfYm94fD4=
所属报告:
泽璟制药(688266)-A股公司研究报告:在研管线临床优势突出商业化产品稳步推进-250815(36页).pdf
打包全文图表
相关数据
图12塔拉妥单抗后分季销售额(百美元)
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
收藏
行业数据
2025-12-23
原图定位
查看详情
图19、塔拉妥单抗的T细胞与肿瘤细胞衔接作用
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
收藏
行业数据
2025-08-19
原图定位
查看详情
图16、小细胞肺癌各阶段美国患者数与塔拉妥单抗相关的临床布局
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
收藏
行业数据
2025-08-19
原图定位
查看详情
图23、塔拉妥单抗上市后销售额(百万美元)
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
收藏
行业数据
2025-08-19
原图定位
查看详情
2024NCCN指南首次将塔拉妥单抗列入ES-SCLC二线治疗的首选方案
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
收藏
行业数据
2025-05-13
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
塔拉妥单抗(Tarlatamab)是具有革命性意义的实体瘤 CD3/DLL3 T细胞衔接器疗法。DLL3/CD3双抗塔拉妥单抗已获 FDA获批上市,适应症为铂类化疗期间或之后疾病进展的 ES-SCLC,成为全球首款获批上市的靶向 DLL3药物。SCLC的特点在于肿瘤浸润淋巴细胞水平低,与 NSCLC 比较,表达水平最低的是 CD8:比肺腺癌低 5.4倍,比肺鳞癌低 6倍,相对于 NSCLC等对免疫治疗敏感的肿瘤类型,SCLC 的疗效仍不令人满意。塔拉妥单抗通过以下步骤发挥抗肿瘤活性:1)一个结合臂特异性地识别并结合 DLL靶点,另一个结合臂则结合 T细胞表面的 CD3 复合物;2)塔拉妥单抗将 T 细胞和肿瘤细胞拉近并形成“免疫突触”,启动了 T细胞的杀伤程序;3)被激活的 T细胞会释放其细胞毒性颗粒,对表达 DLL3的细胞进行杀伤。
行业数据
原图定位
当前图表所属:
泽璟制药(688266)-A股公司研究报告:在研管线临床优势突出商业化产品稳步推进-250815(36页).pdf
表9、肝癌一线免疫疗法与抗血管疗法联用临床数据
表8、1线宫颈癌主要疗法数据
表4、PD-(L)1/TIGIT双抗在研进度
表2、公司高管团队与核心技术人员
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》